Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors Meeting Abstract
| Authors: | Bendell, J. C.; Strauss, J. F.; Fakih, M.; McRee, A. J.; Hendifar, A. E.; Rosen, L. S.; Cercek, A.; Rowinsky, E. K.; Szarek, M.; Gonsalves, F.; Kurth, I.; Andreu, C.; Busby, R.; Spector, S.; Darst, D. M.; Tavazoie, M.; Raza, S.; Lebaka, N.; Wasserman, R.; Janjigian, Y. Y. |
| Abstract Title: | Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Start Page: | 166s |
| Language: | English |
| ACCESSION: | WOS:000560368301400 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.3504 |
| Notes: | Meeting Abstract: 3504 -- Source: Wos |
